Holen Sie sich die Stockscreener-App
127.18
2.49%
3.09
Handel nachbörslich:
127.33
0.15
+0.12%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$124.09
Offen:
$124.54
24-Stunden-Volumen:
8.17M
Relative Volume:
1.19
Marktkapitalisierung:
$58.24B
Einnahmen:
$29.05B
Nettoeinkommen (Verlust:
$8.11B
KGV:
19.70
EPS:
6.4563
Netto-Cashflow:
$9.16B
1W Leistung:
+3.77%
1M Leistung:
+3.56%
6M Leistung:
+24.08%
1J Leistung:
+43.77%
1-Tages-Spanne:
$123.32
$127.36
1-Wochen-Bereich:
$121.80
$127.68
52-Wochen-Spanne:
$86.08
$127.68
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Vergleichen Sie GILD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
127.18 | 153.96B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,030.05 | 914.44B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
200.00 | 480.85B | 92.15B | 25.12B | 20.46B | 10.36 |
|
AMGN
Amgen Inc
|
343.99 | 184.00B | 35.89B | 7.01B | 11.54B | 12.94 |
|
ABBV
Abbvie Inc
|
233.87 | 413.57B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
96.43 | 230.48B | 63.90B | 19.05B | 13.05B | 7.5596 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences I - GuruFocus
Gilead joins partners for delivery of first shipments of breakthrough twice-yearly lenacapavir for HIV prevention to sub-Saharan Africa - European AIDS Treatment Group
Gilead Sciences’ (GILD) chief commercial officer sells $3.5m in stock - Investing.com UK
Raiffeisen Bank International AG Trims Position in Gilead Sciences, Inc. $GILD - MarketBeat
Nomura Asset Management Co. Ltd. Trims Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD is LSV Asset Management's 9th Largest Position - MarketBeat
Thoroughbred Financial Services LLC Has $1.10 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Ontario Teachers Pension Plan Board - MarketBeat
Gilead Sciences, Inc. $GILD Position Boosted by Citizens Financial Group Inc. RI - MarketBeat
Gilead (GILD) Begins Shipments of HIV Prevention Drug to Africa - GuruFocus
Gilead ships first lenacapavir doses to sub-Saharan Africa - StreetInsider
Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa - Business Wire
Cetera Investment Advisers Purchases 21,966 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead single tablet regimen of Bictegravir, Lenacapavir for HIV-1 meets primary endpoint in Phase 3... - Medical Dialogues
Before GLP-1s, a Great Pricing Battle Played Out in Hep C Market - BioSpace
Is It Too Late to Reassess Gilead After Recent Drug Trial Success? - simplywall.st
Will Gilead Sciences Inc. stock deliver long term returnsJuly 2025 Patterns & Verified Chart Pattern Trade Signals - newser.com
Gilead Sciences's Options: A Look at What the Big Money is Thinking - Benzinga
Universal Beteiligungs und Servicegesellschaft mbH Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stake Raised by Westpac Banking Corp - MarketBeat
Letko Brosseau & Associates Inc. Reduces Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Persistent Asset Partners Ltd Invests $767,000 in Gilead Sciences, Inc. $GILD - MarketBeat
Foundations Investment Advisors LLC Buys 17,318 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Creative Planning Increases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Where speed meets science in Gilead’s approach to drug development - Endpoints News
Crossmark Global Holdings Inc. Sells 39,563 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by Cornerstone Advisors LLC - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by Avantax Advisory Services Inc. - MarketBeat
Alberta Investment Management Corp Lowers Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Will Gilead Sciences Inc. (GIS) stock outperform energy sector in 2025Weekly Investment Recap & Fast Gain Stock Trading Tips - newser.com
Westwood Holdings Group Inc. Acquires 11,145 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Intech Investment Management LLC Buys 74,506 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
OmniStar Financial Group Inc. Increases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Intrua Financial LLC Sells 4,494 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Will Gilead Sciences Inc. (Common Stock) (GIS0) stock outperform Dow JonesWeekly Earnings Recap & Verified Momentum Stock Alerts - newser.com
Arvest Bank Trust Division Cuts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Advisors Capital Management LLC Cuts Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) Upgraded at Wall Street Zen - MarketBeat
Scotiabank Analyst Sees Opportunity in Large Cap Biopharma, Keeps Outperform on GILD - Finviz
Will Gilead Sciences Inc. stock sustain high P E ratiosJuly 2025 Trade Ideas & Verified Entry Point Detection - newser.com
Ethiopia confirms first outbreak of Marburg virus after testing - The Spokesman-Review
Insider Selling: Gilead Sciences (NASDAQ:GILD) EVP Sells 53,646 Shares of Stock - MarketBeat
Using data tools to time your Gilead Sciences Inc. exitPortfolio Gains Report & Real-Time Sentiment Analysis - newser.com
Zacks Research Forecasts Lower Earnings for Gilead Sciences - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by Wrapmanager Inc. - MarketBeat
Gilead Sciences (NASDAQ:GILD) Raised to Strong-Buy at Scotiabank - MarketBeat
Grandfield & Dodd LLC Has $24.50 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Is this a good reentry point in Gilead Sciences Inc.2025 Macro Impact & Breakout Confirmation Trade Signals - newser.com
PNC Financial Services Group Inc. Purchases 8,023 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
ABN Amro Investment Solutions Takes $5.30 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) Nasdaq Today Shows Drug-Innovation - Kalkine Media
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.34%
0.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):